Introduction
therapy with loop diuretics and distally active agents may be effective, even in patients with advanced renal When the heart fails the kidney retains sodium. Initially failure [3, 4] . However, this so-called sequential this is a beneficial counter-regulatory response to mainnephron blockade can induce severe electrolyte disturbtain the effective arterial volume, but the down-side is ances, in particular hypokalaemia and hypomagnesaean increased preload due to volume retention, which mia. In this context potassium-sparing diuretics may may perpetuate and even aggravate congestive heart be useful adjuncts to therapy. The aldosterone receptor failure (CHF ). Diuretics counteract the sodium retenblocking agent spironolactone may have a special role tion and are therefore indispensable in most patients in this setting, since it provides blockade at a more with clinical heart failure. These drugs are clearly distal nephron segment, as will be discussed below. It effective to reverse symptoms of congestion, but little should be emphasized that a reduction of sodium information on their overall effect on prognosis is intake will lower urinary potassium wasting and thereavailable. This point is important, since diuretics have fore reduce the risk of hypokalaemia. This is due to several, potentially even life-threatening, side-effects.
the fact that less sodium is presented to the nephron A recent study has shed new light on a major problem segment where potassium for sodium exchange takes regarding diuretic treatment in patients with CHF.
place. A low-sodium diet will also help achieve a Discussion of this study requires a review of some of negative sodium balance, which is the ultimate goal of the issues concerning current diuretic therapy to put any rational oedema-reducing therapy. the problem into perspective.
Electrolyte disturbances Volume overload-oedema
Afterload reduction with angiotensin-converting Patients with CHF may present with massive oedema. enzyme (ACE) inhibitors reduces mortality in patients It is notoriously difficult to overcome the sodium with symptomatic and even asymptomatic left ventricuretention in CHF. This is a compensatory response to lar dysfunction. Secondary hyperaldosteronism often the decrease in effective arterial volume and any further persists, however, despite effective ACE inhibition. reduction in the effective arterial volume by diuretics Consequently patients with CHF tend to develop hypomay precipitate renal and/or circulatory failure. kalaemia even when they are not on diuretics, particuFurthermore, reducing preload by diuretics may larly when the sodium intake is high. In patients with worsen cardiac function, particularly in patients with CHF severe hypokalaemia (and hypomagnesaemia) right ventricular failure, although in many patients a may develop, especially when high doses of diuretics reduction of preload and cardiac size brings the heart are administered. Such hypokalaemia is not an innointo a more favourable range of the Franck-Starling cent academic phenomenon, but a potentially lifecurve, thus increasing stroke volume [1] .
threatening complication: patients with reduced left Some patients with advanced heart failure may be ventricular function have an increased incidence of resistant to even large doses of loop diuretics despite severe cardiac dysrrhythmia and this tendency is apparently normal renal function [2] . One important aggravated by electrolyte disturbances. reason for the refractoriness to loop diuretics is the When hypertensive patients are treated with high so-called rebound effect after single doses of loop doses of diuretics the incidence of sudden cardiac death diuretics, which is characterized by a disproportionis increased [5, 6 ] . At the 1998 meeting of the American ately increased sodium avidity of the kidney after the Heart Association in Dallas a correlation was reported diuretic action has worn off. This rebound effect may between diuretic dose and sudden death in patients be overcome by a more frequent administration or the with advanced heart failure; this finding was based on continuous infusion of loop diuretics. Should diuretic a retrospective analysis of the PRAISE trial [7] . In acute heart failure an association has also been found to prognosis may at least partially be offset by fatal itors which have become the backbone of modern cardiac dysrhythmia. CHF therapy [11] . The mechanism(s) underlying the In order to reduce the risk of arrhythmia, patients so-called aldosterone escape are not known. with CHF often receive oral potassium supplements, Hyperaldosteronism favours the development of hypoalthough this form of therapy is relatively ineffective kalaemia and aggravates oedema formation. In addifor the prevention of potassium depletion. The cardiac tion to these clinically undesirable effects, aldosterone risk of diuretic therapy can be reduced by prescribing may also lead to structural changes of the heart, low doses of diuretics and/or by the use of potassium-particularly cardiac hypertrophy and myocardial fibsparing agents [6 ] . In this context the aldosterone rosis [12] . Aldosterone-induced structural changes may antagonist spironolactone has recently received much contribute to the development of arrhythmia and attention (RALES study; see below).
adversely affect survival. Therefore it seems reasonable With appropriate caution potassium-sparing drugs to block the cellular actions of aldosterone with may be added to the diuretic regimen even in patients spironolactone. This approach is fraught with the risk who are simultaneously treated with ACE inhibitors. of hyperkalaemia, especially in patients who are on Such a combination requires meticulous monitoring of ACE inhibitors. The safety of the simultaneous treatthe serum concentration of potassium and creatinine, ment with spironolactone and ACE inhibitors has been since a deterioration of renal function could rapidly a major concern. This issue was addressed in a mulresult in life-threatening hyperkalaemia. It is useful to ticentre trial in patients with CHF. The randomized remember that reduction of sodium intake, apart from aldactone evaluation study (RALES ) enrolled 214 decreasing oedema formation and diuretic require-patients with congestive heart failure NYHA II-IV ments, reduces urinary potassium loss. A low-sodium [13] . Spironolactone was added in a placebo-controlled diet is therefore mandatory in patients with heart fashion to the previous therapeutic regimen which failure-even if hyponatraemia is present. A detailed included an ACE inhibitor and a loop diuretic. discussion of the complex pathophysiology of hypona-The doses of spironolactone ranged from 12.5 to traemia in (diuretic-treated) patients with heart failure 75 mg daily. The incidence of hyperkalaemia is beyond the scope of this editorial. Suffice it to say ( K+Á5.5 mmol/l ) was 5% in patients treated with that hyponatraemia mostly results from free water 12.5 mg spironolactone per day and 13% in patients excess and not from sodium depletion. The treatment receiving 25 mg spironolactone per day; higher doses of choice is therefore restriction of free water intake. induced hyperkalaemia in up to 24% of patients. In When this is difficult to achieve in patients with the placebo group the incidence of hyperkalaemia was advanced heart failure, there may be a case for vaso-5%. Hypokalaemia ( K+<3.4 mmol/l ) was observed pressin antagonists-a new class of drugs on the in 0.5% of the treatment group and in 10% of the horizon.
placebo group. The major conclusion of the RALES study was that in patients with CHF receiving ACE inhibitors, low doses of spironolactone (up to
Neurohumoral activation
25 mg/day) are safe and can effectively reduce the risk of hypokalaemia. Having established the safety/dosage In addition to causing electrolyte disturbances, diur-of spironolactone the effect of spirolactone on mortaletics exert adverse cardiovascular effects by inducing a ity was evaluated in a multicentre placebo-controlled variety of neurohumoral alterations. Acute treatment follow-up RALES trial on 1663 patients with severe with diuretics causes sympathetic activation [9] thus CHF(NYHA III-IV ). This study was terminated early increasing the propensity to develop dysrrhythmia. because of a significantly reduced mortality in the Chronic treatment with furosemide, however, decreases spironolactone group: yet unpublished data presented resting (but not exercise-induced) plasma noradrena-at last year's meeting of the American Heart line concentration, while the renin-angiotensin-Association in Dallas indicated a 27% decrease of aldosterone system is activated [10] . Regimens recently mortality and a 36% reduction in CHF-related hospiproposed for the management of CHF include ACE talizations. However, it is currently not clear whether inhibitors and-in selected patients-low-dose beta chronic aldosterone blockade affects cardiac structure blockers. The latter should reduce neuroendocrine in patients with CHF (as it does in animals), but activation, but ACE inhibitors do not prevent the reduction of vascular collagen turnover, improvement development of secondary hyperaldosteronism (see of heart rate variability, and reduction of the early below).
morning increase in heart rate were noted [14] . The preliminary data from the RALES study suggest that these desirable effects translate into an improved Persistent hyperaldosteronism-should all patients prognosis. It is unclear whether there are significant receive spironolactone? Evidence from the RALES differences between spironolactone and other potasstudy sium-sparing diuretics in this respect.
Hyperaldosteronism plays an important role in the pathophysiology of congestive heart failure, even in Acknowledgement. Introduction large-scale intention-to-treat trials. On the other hand, there are those who admit that the effect is limited, The issue whether dietary protein restriction and phar-but claim this is so only because compliance is less macological intervention retard the progression of than optimal. This debate goes beyond the fate of chronic renal insufficiency (CRI ) in man is extremely individual CRI patients, since postponing the need for important. Its repercussions go beyond dialysis logistics dialysis can save the community a large amount of and extend to issues such as patient suffering and the money. social and economic impact of regular replacement therapy (RRT ). However, in the prospective of the Statistical relevance patient, what he or she wants to know most is: 'how Although the conclusions of four prospective randomlong will I be free of dialysis if I follow therapeutic ized and controlled trials [1] [2] [3] [4] were inconsistent, the prescriptions?' and 'which is the most effective and pooled results [5] showed that a low protein diet least demanding therapy?'.
reduced the risk of renal failure or death in nondiabetic patients by 33% and this was statistically significant. Moreover, the pooled results of five studies
